ABC | Volume 114, Nº5, May 2020

Statement Brazilian Cardiology Society Statement for Management of Pregnancy and Family Planning in Women with Heart Disease – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 191. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-26. 192. Maron BJ, Gardin JM, Gflack JM, Giddingm SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in the general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronay Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785-9. 193. Goland S, van Hagen IM, Elbaz-Greener G, Elkayam U, Shotan A, Merz WM, et al. Pregnancy inwomenwith hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J;38(35):2683-90. 194. AvilaWS, Amaral CM, Ramires JA, Rossi EG, GrinbergM, BortolottoMR, et al. Influência da gestação na evolução clínicamaterno-fetal de portadoras de cardiomiopatia hipertrófica. Arq Bras Cardiol. 2007;88(4):480-5. 195. Tanaka H, Kamiya C, Katsuragi S, Tanaka K, Miyoshi T, Tsuritani M, et al. Cardiovascular events in pregnancy with hypertrophic cardiomyopathy. Circ J. 2014;78(10):2501-6. 196. Watkins H,MacKennaWJ, Thierfelder L.Mutations in thegenes for cardiac troponin T and a-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332(16):1058-64. 197. Maron BJ, Moller JH, Seidman CE, Vincent GM, Dietz HC, Moss AJ, et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, andMarfan syndrome: a statement for healthcare professionals from councils on clinical cardiology, Cardiovascular disease in the young and basic science. American Heart Association. Circulation. 1998;98(14):1460-71. 198. Agir A, Bozyel S, Celikyurt U, Argan O, Yilmaz I, Karauzum K, et al. Arrhythmogenic right ventricular cardiomyopathy in pregnancy. Int Heart J. 2014;55(4):372-6. 199. Doyle NM, Monga M, Montgomery B, Dougherty AH. Arrhythmogenic right ventricular cardiomyopathy with implantable cardioverter defibrillator placement in pregnancy. J Maternal Fetal Neonatal Med. 2005;18(2):141-4. 200. Kilic ID, Tanriverdi H, Evrengul H, Uslu S, Sungur MA Left ventricular non- compaction in pregnancy. Cardiovasc J Afr. 2013;24(3):e1-2. 201. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-78. 202. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-8. 203. BelloNA,AranyZ.Molecularmechanismsofperipartumcardiomyopathy:a vascular/hormonalhypothesis.TrendsCardiovascMed.2015;25(6):499-504. 204. Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf). 2002;57(5):609‑13. 205. Hilfiker‑Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, etal.AcathepsinD‑cleaved16kDa formofprolactinmediatespostpartum cardiomyopathy. Cell. 2007; 128(3):589‑600. 206. Hilfiker‑KleinerD,SliwaK,DrexlerH.Peripartumcardiomyopathy:Recent insights in its pathophysiology. Trends CardiovascMed. 2008;18(5):173‑9. 207. Halkein J, Tabruyn SP, Ricke-HochM, Haghikia A, NguyenNQ, Scherr M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143-54. 208. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-73. Erratum in: Circulation. 2010;121(21):e425. 209. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A. Bromocriptine for the treatment of peripartumcardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671-9. 210. de Jong JS, Rietveld K, van Lochem LT, Bouma BJ. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur J Heart Fail. 2009;11(2):220-2. 211. Melo MA, Carvalho JS, Feitosa FE, Araujo Júnior E, Peixoto AB, Costa Carvalho FH, et al. Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome. Rev Bras Ginecol Obstet. 2016;38(6):308-13. 212. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review andmeta-analysis. J Am Coll Cardiol. 2013;62(18):1715-23. 213. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of PregnancyAssociated Cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905-14. 214. SliwaK,Anthony J.Latemate rnaldeaths:aneglectedresponsibility.Lancet . 2016;387(10033):2072-3. 215. Vega CE, Soares VM, Nasr AM. Mortalidade materna tardia: comparação de dois comitês de mortalidade materna no Brasil. Cad Saúde Pública. 2017;33(3):e00197315. 216. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J AmHeart Assoc. 2014;3(3):e001056. 217. Goland S, Bitar F, Modi K, Safirstein J, Ro A, Mirocha J, et al. Evaluation of the Clinical Relevance of Baseline Left Ventricular Ejection Fraction as a Predictor of Recovery or Persistence of Severe Dysfunction in Women in the United States With Peripartum Cardiomyopathy. J Card Fail. 2011;17(5):426-30. 218. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36(18):1090-7. 219. Bouabdallaoui N, Mouquet F, Lebreton G, Demondion P, Le Jemtel TH, Ennezat PV. Current knowledge and recent development onmanagement of peripartum cardiomyopathy. Eur Heart J Acute Cardiovasc Care. 2017;6(4):359-66. 220. Rasmusson K, Brunisholz K, Budge D, Horne BD, Alharethi R, Folsom J, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012;31(2):180-6. 221. Sliwa K, Petrie MC, Hilfiker-Kleiner D, Mebazza A, Jackson A, Johnson MR, et al. Long-term proegnosis subsequent pregnancy contraception and overall management of peripartum cardiomyopathy. Eur J Heart Fail. 2018;20(6):951-62. 222. Bauersachs J, Konig T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, HamdanR, Jackson AM, Forsyth P, Boer AR, Mueller C, Lyon RA, Lund HL, Piepoli MF, Heymans S, CChioncel O, Anker D S, Ponikowski P, Seferovic P, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(9):827-843. 223. Sousa AGMR, Timerman A.Doença arterial coronária-Peculiaridades na mulher Reposição Hormonal. Cap.38.1ª edição-Atheneu 224. Gibson P, Narous M, Firoz T, Chou D, Barreix M, Say L, et al. Incidence of myocardial infarction in pregnancy: a systematic reviewandmeta-analysis of population-based studies. Eur Heart J Qual Care Clin Outcomes. 2017;3(3):198-207. 935